Long-term Impact of Pneumococcal Conjugate Vaccine on Carriage
Completed
Conditions studied: Pneumococcal Infections
In brief
Pneumococcus is a major cause of morbidity and mortality. In 2000, a pneumococcal conjugate vaccine (PCV) was licensed for use in children and is now part of the routine childhood vaccine schedule. PCV is known to reduce invasive disease and protect against nasopharyngeal (NP) acquisition of vaccine serotype pneumococci; it also results in an increased risk of nonvaccine serotype carriage. This study proposes to assess the longterm impact of vaccine on NP carriage in a setting where there is intense antibody pressure on the ecology of the pneumococcus. A cross sectional study of pneumococcal NP colonization among American Indian children will be combined with surveillance for invasive disease in the same population. The purpose is to determine the impact of community wide PCV use on NP colonization and the relationship with invasive disease. This longterm safety issue needs to be assessed to fully evaluate the impact of vaccine on NP ecology and invasive disease.
Key facts
- Study ID
- NCT00294021
- Run by
- Johns Hopkins Bloomberg School of Public Health
- People needed
- 1000
- Starts
- 2006-03-01
- Expected to finish
- 2008-04-01
- Last updated by the study team
- 2012-09-26
Who can join
Age: any. Sex: any. Healthy volunteers: accepted.
Where it is running
- Johns Hopkins Center for American Indian Health — Chinle, Fort Defiance, Whiteriver, AZ; Gallup, Shiprock, NM, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.